Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
about
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV)Impact of new treatment options for hepatitis C virus infection in liver transplantationInterferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipientsAnti-hepatitis C virus drugs and kidneyRecommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National GuidelineHepatitis C Virus and Liver Transplantation.Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus InfectionEfficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients.Use of Hepatitis C-Positive Donor Livers in Liver Transplantation.Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence.Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrenceInterferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.Is it time to rethink combined liver-kidney transplant in hepatitis C patients with advanced fibrosis?Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study.Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis.The future of liver transplantation for viral hepatitis.Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation.Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin."Targeting" hepatitis C after liver transplantation.Prophylaxis of HCV reinfection and direct-acting antiviral agents during liver transplantation.Direct-acting Antiviral Agents in Hepatitis C Virus-infected Renal Allograft Recipients: Treatment and Outcome Experience from Single Center.
P2860
Q26740319-7F2A5635-71E2-4C2E-8381-82F4EB9B5E10Q26782017-E3AF250C-7AD2-48F1-93F7-CC9463EB059AQ26795595-7A54402D-FECD-4D8C-898E-EE5C99C370C1Q28070279-00D43F9D-17F4-4D59-BAEF-4D27EC92BEB2Q28076883-5EEF73AF-6D0F-4C9A-B13A-7D7BC472B785Q33717116-A8AA2E90-FB3D-40B6-828A-1DB6CB63AA3FQ36077546-8FECFAAE-E477-47FE-A523-7965BF2F9379Q36165389-B59973EC-5FBE-4DE4-9009-7FD4A67EDE94Q36292616-974774C8-D54A-4741-BF2C-4B787A0DF341Q36875036-A9B0B5D6-6175-453C-B18A-E9E4ED14348FQ37349067-8B028B8D-DB37-4C1C-9478-ECE90C4D0377Q37552703-4BA4A9BE-CE07-4C6B-97D5-8BD3A9AB64DDQ37651918-AE366D8B-149D-4468-938C-9D9769DD4AF9Q38384095-B4C85D0A-95C1-491C-9BBE-6DED68723745Q38769679-597939CC-FCB6-4CB6-A2FE-EDC99B29FE20Q38774864-25BDA985-7EE9-4F5E-91AC-C82356CFDA91Q38845669-C9E8D04C-784E-41B3-B412-D873B9658F4EQ38859081-44B0E030-2DA8-4A1E-A750-E7FD698FED29Q38872799-1712B69A-45A9-4BAB-8D44-82A1A5FD00F5Q38954096-FBD2BC0A-437E-4D4E-9C60-447E13797E8CQ39108672-442C27C6-941B-4436-9AFF-4F887A9DDD72Q39139767-09AA7DF7-A4AD-476B-B9D7-3C35FAAB2BF5Q39609174-0A92C986-27A4-4846-9A7E-6EFB9AD1414BQ39885523-F22EDCE4-BB46-4D61-9EE7-1C9F3082A7EFQ39968319-4B386721-9448-4002-A871-B14F15E8A7F5Q40141719-F849C473-F4EC-4FA3-8143-0F053ED1B8A7Q40278284-05AC9154-5798-494A-8674-5BD016F97708Q40291443-1322287D-57E4-4D92-88A1-55E7A54FF249Q40352380-D8FB7BC1-BC80-4174-B25B-2565DFA5463AQ40373543-8753FD95-0F2F-4927-9A80-1AE8BE3D706AQ40400190-F0710DF8-DCF5-48A7-B172-1D81CD601BDDQ40473486-E074BB36-663F-4C57-9B6C-DC9ABE5E7842Q40584810-B6CD2B84-0450-4309-B262-6B45A4B38C56Q40635393-A5B0E8B9-8426-473F-8710-B2CF247806BCQ40705980-3A6F7DB9-D020-4574-85A9-7083D009BD0FQ42148776-68340D22-F382-4988-B5A3-2B087C6A7168Q42984704-07A4771D-4CBB-484C-9CE5-D56FD720F76FQ51000411-1B776E65-12C7-4AE1-ABAC-B0D9CA040940Q55353924-F77FC1E9-025A-4437-B608-A7FA3FF47558
P2860
Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sofosbuvir and simeprevir for ...... n liver transplant recipients.
@en
type
label
Sofosbuvir and simeprevir for ...... n liver transplant recipients.
@en
prefLabel
Sofosbuvir and simeprevir for ...... n liver transplant recipients.
@en
P2093
P2860
P356
P1476
Sofosbuvir and simeprevir for ...... in liver transplant recipients
@en
P2093
Adam Peyton
Andres F Carrion
Christopher O'Brien
Danny Avalos
Julio A Gutierrez
Kalyan Ram Bhamidimarri
Paul Martin
P2860
P304
P356
10.1002/LT.24126
P577
2015-06-01T00:00:00Z